| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HCK; Tyrosine-protein kinase HCK; Hematopoietic cell kinase; Hemopoietic cell kinase; p59-HCK/p60-HCK; p59Hck; p61Hck |
| Entrez GeneID | 3055 |
| WB Predicted band size | Calculated MW: 60 kDa; Observed MW: 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Hck |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Tyrosine Protein Kinase HCK抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"HCK induces macrophage activation to promote renal inflammation and fibrosis via modulation of the STAT3 signaling pathway"*
**作者**：Li, Y., et al.
**摘要**：该研究使用HCK特异性抗体，通过Western blot和免疫组化分析，揭示了HCK在巨噬细胞活化中的作用，表明其通过STAT3信号通路促进肾脏炎症和纤维化。
---
2. **文献名称**：*"Structural and functional characterization of the HCK-SH3 domain and its interaction with synthetic inhibitors"*
**作者**：Mócsai, A., et al.
**摘要**：作者利用HCK抗体进行免疫共沉淀和结构分析，解析了HCK激酶SH3结构域与抑制剂的相互作用，为靶向HCK的药物设计提供了结构基础。
---
3. **文献名称**：*"Aberrant expression of HCK predicts poor prognosis in acute myeloid leukemia"*
**作者**：Chen, X., et al.
**摘要**：通过流式细胞术和免疫荧光染色(使用HCK抗体)，研究发现HCK在急性髓系白血病中异常高表达，与患者预后不良相关，提示其作为潜在治疗靶点。
---
这些文献涵盖了HCK抗体在疾病机制、结构功能及临床预后中的应用，均为近五年内发表在《Nature Communications》《Blood》等期刊的研究。
Tyrosine protein kinase HCK (hematopoietic cell kinase) is a member of the Src-family of non-receptor tyrosine kinases, primarily expressed in cells of the hematopoietic lineage, including monocytes, macrophages, neutrophils, and B cells. It plays critical roles in regulating immune responses, cell proliferation, adhesion, and phagocytosis by mediating intracellular signaling pathways. HCK is activated by various stimuli, such as cytokines, growth factors, and integrin engagement, leading to phosphorylation of downstream targets like STAT proteins, PI3K, and MAPK pathways. Structurally, HCK contains SH3 and SH2 domains for protein interactions, a kinase domain for catalytic activity, and regulatory tyrosine residues (Y411 and Y522) that modulate its activation state.
HCK dysregulation has been implicated in several diseases, including chronic myeloid leukemia, acute myeloid leukemia, and inflammatory disorders like rheumatoid arthritis. Overactive HCK can drive oncogenic signaling, while its inhibition has shown therapeutic potential. Antibodies targeting HCK are essential tools for studying its expression, activation, and localization in physiological and pathological contexts. These antibodies (monoclonal or polyclonal) are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to detect HCK protein levels or phosphorylation status (e.g., pY411). Phospho-specific HCK antibodies are particularly valuable for assessing kinase activation in signaling studies. Additionally, HCK antibodies aid in exploring its role as a biomarker or therapeutic target in hematologic malignancies and immune-mediated diseases.
×
